We equip customers with key advantages through nanolithography solutions
We equip customers with key advantages through nanolithography solutions
Erbjudandet i korthet
Emittent: Obducat AB (publ)
Villkor: En (1) teckningsoption berättigar till teckning av en (1) ny stamaktie av serie B
Teckningskurs: 0,79 SEK
Teckningsperiod: 27 februari–9 mars 2023
ISIN-kod TO15: SE0018041873
Marknadsplats: NGM Main Regulated Equity
Sista dag för handel: 2023-03-06
Explore Nanolithography
Obducat customer Sorrento Therapeutics reports positive results
The biopharmaceutical company Sorrento Therapeutics reports positive trial results utilizing Sofusa Lymphatic Delivery of the biological medical product Etanercept after completing its first phase 1b human proof of concept study.
Obducat gives presentation on ”Nanoimprint Lithography (NIL)-Based Patterning of Chemically Strengthened Glass Sheets”
The presentation will be held at the EIPBN conference - 65th International Conference on Electron, Ion and Photon Beam Technology and Nanofabrication, which will take place between May 31 and June 3, 2022, in New Orleans, Louisiana.
Is this where your Obducat story begins? We are currently looking for new talents
Do you enjoy an international work environment and seek to drive change? Are you passionate about nanotechnology, sales, engineering and consider yourself to be a contributing team player? Check out our job opportunities below.
Obducat is an innovative developer and world-leading supplier of micro-and nano lithography solutions. We supply the technology, products and processes used for advanced micro- and nanopatterning of surfaces.
